What is the appropriate treatment for a gastric ulcer?

Treatment of Gastric Ulcer

Start all patients with gastric ulcers on a proton pump inhibitor (PPI) twice daily and test every patient for H. pylori infection before discharge. 1

Immediate Pharmacologic Management

Acid Suppression Therapy

• Initiate PPI therapy immediately for all patients with gastric ulcers, as PPIs are the cornerstone of ulcer healing 1, 2
• For bleeding ulcers with high-risk stigmata (active spurting, visible vessel, adherent clot), administer IV PPI as a loading dose followed by continuous infusion for 72 hours after endoscopic hemostasis 1
• After 72–96 hours of IV PPI, transition to oral PPI twice daily for 14 days, then switch to once-daily dosing 3, 1
• Continue once-daily PPI after ulcer healing for a duration determined by the underlying cause (indefinite if NSAID use continues, until H. pylori eradication is confirmed, or 4-8 weeks for idiopathic ulcers) 1
• Do not use H₂-receptor antagonists for acute ulcer management as they are inferior to PPIs 1

Alternative Acid Suppression: P-CABs

• Potassium-competitive acid blockers (P-CABs) like vonoprazan are noninferior to PPIs for gastric ulcer healing (94% healing at 8 weeks with vonoprazan 20 mg vs lansoprazole 30 mg) 4
• However, do not use P-CABs as first-line therapy for uncomplicated peptic ulcers due to higher costs and limited availability; reserve them for PPI failures 4
• P-CABs may be particularly useful for ulcer prophylaxis in high-risk patients (those with ulcer history requiring long-term aspirin or NSAIDs), showing 0.5–1.5% recurrence vs 2.8% with lansoprazole 4

H. pylori Testing and Eradication

Testing Strategy

• Test every patient with a gastric ulcer for H. pylori before discharge 3, 1
• Available diagnostic tests include: urea breath test (sensitivity 88–95%, specificity 95–100%), stool antigen test (sensitivity 94%, specificity 92%), or endoscopic biopsy 3, 1
• Repeat any negative H. pylori test obtained during acute bleeding because false-negative results are common in the setting of active hemorrhage 1

Eradication Regimens

First-Line Therapy (when local clarithromycin resistance <15%):

• Standard triple therapy for 14 days: PPI twice daily + clarithromycin 500 mg twice daily + amoxicillin 1000 mg twice daily 3, 1
• For penicillin-allergic patients: substitute metronidazole 500 mg twice daily for amoxicillin 3
• Start this regimen after 72–96 hours of IV PPI therapy in bleeding ulcers 3

Alternative First-Line (when clarithromycin resistance is high):

• Sequential therapy for 10 days: Days 1–5: PPI twice daily + amoxicillin 1000 mg twice daily; Days 6–10: PPI twice daily + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily 3, 1
• This regimen requires strict adherence to the sequential dosing schedule 3

Second-Line Therapy (if first-line fails):

• Levofloxacin-based triple therapy for 10 days: PPI twice daily + levofloxacin 500 mg once daily (or 250 mg twice daily) + amoxicillin 1000 mg twice daily 3, 1

P-CAB-Based Eradication:

• Use P-CABs (vonoprazan) in place of PPIs for H. pylori eradication as they achieve higher eradication rates (92% vs 80% with PPIs), particularly in patients with antimicrobial-resistant infections 4
• This is one of the few indications where P-CABs should be preferred over PPIs due to superior efficacy and short treatment duration minimizing cost concerns 4

Confirmation of Eradication

• Confirm H. pylori eradication after completing therapy using urea breath test or stool antigen test 1
• Failure to eradicate H. pylori results in 26% rebleeding rate in patients with bleeding ulcers 3, 1

NSAID and Antiplatelet Management

Stopping Risk Medications

• Discontinue NSAIDs immediately if possible 2, 5
• If NSAIDs cannot be stopped, treat the ulcer with PPIs and continue PPI therapy as long as NSAIDs are used 2, 5

Resuming Antiplatelet Therapy

• In patients with established cardiovascular disease who develop ulcer bleeding, restart low-dose aspirin within 1–7 days (ideally 1–3 days) once bleeding is controlled 1
• Do not prematurely discontinue aspirin as cardiovascular mortality risk outweighs bleeding risk 1

Ulcer Prevention in High-Risk Patients

For patients with ulcer history requiring continued NSAIDs:

• Prescribe a COX-2 selective inhibitor (celecoxib) together with a PPI as this combination is superior to either agent alone 1, 2
• Do not use COX-2 inhibitor or PPI alone in patients with prior ulcer bleeding requiring NSAIDs 1

For patients with ulcer history requiring low-dose aspirin:

• Add PPI therapy to all patients on single or dual antiplatelet regimens who have had prior ulcer bleeding 1
• PPIs or vonoprazan are recommended; H₂-receptor antagonists are suggested as an alternative 2

For patients requiring anticoagulation:

• Use concomitant PPI therapy in patients on warfarin or DOACs after ulcer bleeding 1

Endoscopic and Surgical Management

Endoscopic Therapy

• Hospitalize patients for at least 72 hours after endoscopic hemostasis for high-risk stigmata 1
• Endoscopic therapy is the first-line intervention for bleeding ulcers with active bleeding or high-risk stigmata 3

Surgical Intervention

• If endoscopic therapy fails, obtain surgical consultation immediately 1
• Percutaneous arterial embolization may be considered as an alternative to surgery when expertise is available 1
• Surgery is reserved for life-threatening complications including refractory bleeding, perforation, and gastric outlet obstruction 6

Special Populations and Situations

Idiopathic Ulcers (H. pylori-negative, NSAID-negative)

• Treat with antisecretory drugs (PPIs) for 4–8 weeks 5
• Perform repeat endoscopy to verify complete healing and exclude malignancy (gastric cancer, lymphoma) or non-peptic disease (Crohn's disease) 5
• These patients require careful follow-up as the underlying cause is unclear 5

Ulcers in Patients Taking Multiple Risk Medications

• The combination of H. pylori infection and NSAID use significantly increases ulcer risk 7
• Eradicate H. pylori and optimize gastroprotection with PPIs 7

Critical Follow-Up

• Perform repeat endoscopy to verify complete gastric ulcer healing in all patients 5
• Do not rely on symptom resolution alone as gastric ulcers may harbor malignancy 5
• If H. pylori eradication is not documented, treat as treatment failure and retreat 1

Common Pitfalls to Avoid

• Do not accept a single negative H. pylori test during acute bleeding without repeat testing 1
• Do not use standard triple therapy in areas with clarithromycin resistance >15% as eradication rates fall below acceptable thresholds 3
• Do not stop aspirin indefinitely in cardiovascular disease patients due to bleeding concerns 1
• Do not use single-agent gastroprotection (COX-2 inhibitor alone or PPI alone) in high-risk patients requiring NSAIDs after ulcer bleeding 1